On January 23rd, Sanofi announced a merger agreement with biopharmaceutical company Inhibrx, which may strengthen the company's leading position in the fields of rare diseases and inflammatory immunity.
It is reported that through this acquisition, Sanofi intends to treat α- The potential best and rarest disease therapies for anti trypsin deficiency are included in its pipeline.
According to the acquisition agreement, Sanofi will make a prepayment of approximately $1.7 billion ($30 per share) and a contingent value equity of $296 million ($5 per share), while also assuming Inhibrx's debt. (Huo Xingyu)